Market Overview

Edison issues update on Celyad (CYAD)


LONDON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- The FDA's sign off on Celyad's first clinical trial design for its allogeneic NRK CAR T-cell therapy (CYAD-101) is an important milestone. The study, possibly staring in Q4 2018, mirrors the current colorectal SHRINK trial a combination of autologous CYAD-01 therapy with FOLFOX chemotherapy. This gives Celyad the lead in a mass-market solid cancer where allogeneic therapy is likely to be essential. The indicative value has been increased to €1,090m (€89 per share) from €1,040m (€84 per share) pending further data.

The nominal allogeneic value has been increased from €50m to €100m pending further data; it may come to dominate the valuation. This increases the overall indicative value to €1,090m (formerly €1,040m), €89 per share (formerly €84).  Allogeneic therapy is currently a highly-active investment area, for example, the April deal involving Pfizer and pre-clinical Allogene (US$300m start-up funding). 

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Dr John Savin MBA, +44 (0)20 3077 5735
Dr Daniel Wilkinson, +44 (0)20 3077 5734

Learn more at and connect with Edison on: 

Primary Logo

View Comments and Join the Discussion!